Inventor
SHAIR MATTHEW D
US22 patents
⚠️ This page may combine multiple inventors who share the name “SHAIR MATTHEW D”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HARVARD COLLEGE
12 patentsUS7045360B2May 16, 2006
Method for analysis of reaction products
HARVARD COLLEGE25 citations84
US9127019B2Sep 8, 2015
Cortistatin analogues and synthesis thereof
HARVARD COLLEGE7 citations81
US6448443B1Sep 10, 2002
Synthesis of combinatorial libraries of compounds reminiscent of natural products
HARVARD COLLEGE11 citations73
US7109377B2Sep 19, 2006
Synthesis of combinatorial libraries of compounds reminiscent of natural products
HARVARD COLLEGE4 citations62
US9994582B2Jun 12, 2018
Cortistatin analogues and syntheses and uses thereof
HARVARD COLLEGE1 citations60
US9714255B2Jul 25, 2017
Cortistatin analogues and syntheses thereof
HARVARD COLLEGE1 citations60
US12509430B2Dec 30, 2025
Inhibitors of nicotinamide N-methyltransferase, compositions and uses thereof
HARVARD COLLEGE0 citations49
US10508121B2Dec 17, 2019
Cortistatin analogues and syntheses and uses thereof
HARVARD COLLEGE0 citations49
US10273241B2Apr 30, 2019
Cortistatin analogues and syntheses and uses thereof
HARVARD COLLEGE0 citations49
US10202400B2Feb 12, 2019
Cortistatin analogues and syntheses thereof
HARVARD COLLEGE0 citations49
US10273264B2Apr 30, 2019
Cortistatin analogues and syntheses and uses thereof
HARVARD COLLEGE0 citations40
US10273240B2Apr 30, 2019
Cortistatin analogues, syntheses, and uses thereof
HARVARD COLLEGE0 citations40
NUVALENT INC
5 patentsUS11542278B1Jan 3, 2023
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC4 citations71
US11667649B2Jun 6, 2023
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC3 citations69
US12275742B2Apr 15, 2025
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC0 citations59
US12054498B2Aug 6, 2024
Heteroaromatic macrocyclic ether chemotherapeutic agents
NUVALENT INC0 citations59
US12037346B2Jul 16, 2024
Amino-substituted heteroaryls for treating cancers with EGFR mutations
NUVALENT INC1 citations56